

FORM PTO-1149		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0896K		SERIAL NO.: 09/768,917	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Vicari, et al.			
				FILING DATE: January 24, 2001		GROUP:	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AW	AE	WO98/01557	1/15/98				
	AF	WO98/14573	4/9/98				
	AG	WO97/31098	8/28/97				
	AI	WO95/17092	6/29/95				
	AK	WO96/34891	11/7/96				
	AL	WO94/21277	6/29/94				
	AM	WO97/19696	6/5/97				
	AN	WO97/41831	11/13/97				
	AO	WO94/07521	4/14/94				
	AP	WO94/13321	6/23/94				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AW	AQ	Fioretti et al., "Reduced Tumorigenicity and Augmented Leukocyte Infiltration After Monocyte Chemotactic Protein-3 Gene Transfer" <i>J. Immunol.</i> 161(1):342-346. (1998)					
	AR	Dematos et al., 1998, "Pulsing of Dendritic Cells with Cell Lysates from either B16 melanoma or MCA-106 Fibrosarcoma Yields Equally Effective Vaccines Against B16 Tumors in Mice" <i>J Surg. Oncol.</i> 68(2):79-91.					
	AS	Vicari et al., 2000, "Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms" <i>J Immunol.</i> 165:1992-2000.					
	AT						
	AU						
	AV						
EXAMINER /Anne Marie Wehbe/ (10/10/2006)				DATE CONSIDERED 10/10/2006			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Express Mail Label: EV 53310825 US

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/768917
Filing Date	01/24/2001
First Named Inventor	VICARI, Alain P
Art Unit	1633
Examiner Name	Anne Marie Sabrina Wehbe
Attorney Docket Number	SF0896KUS

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
AW		WO 00/09151	02-24-2000	Schering Corporation		


Examiner Signature	/Anne Marie Wehbe/ (10/10/2006)	Date Considered	10/10/2006
-----------------------	---------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0896K		SERIAL NO.: 09/768,917	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: VICARI et al.			
Use several sheets if necessary)				FILING DATE: January 24, 2001		GROUP: TO BE ASSIGNED	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AQ	Youseff, S. <i>et al.</i> , 2000, "CC-Chemokine-Encoding DNA Vaccines Enhance Break down of Tolerance to their Gene Products and Treat Ongoing Adjuvant Arthritis" <i>J. Clin. Invest.</i> 106:361-371						
AR	Xin, K.Q. <i>et al.</i> , 1999, "Immunization of RANTES Expression Plasmid with a DNA Vaccine Enhances HIV-1 Specific Immunity" <i>Clin. Immunol.</i> 92:90-96.						
AS	Sin, J. <i>et al.</i> , 2000, "DNA Vaccines Encoding Interleukin-8 and RANTES Enhance Antigen-Specific Th1-type (CD4+) T-cell-mediated Protective Immunity against Herpes Simplex Virus Type 2 in Vivo." <i>J. Virol.</i> 74:11173-11180.						
AT	Nomura, T. <i>et al.</i> , 2000, "Chemokines and Anti-cancer Immunotherapy" <i>Anticancer Res.</i> 20:4073-4080.						
AU	Lu, Y. <i>et al.</i> , 1999, "Macrophage Inflammatory Protein 1 Alpha Expression Plasmid enhances DNA Vaccine-Induced Immune Response Against HIV-1" <i>Clin Exp. Immunol.</i> 115:335-341.						
AV	Lillard, J.W. <i>et al.</i> , 1999, "Lymphotactin acts as an Innate Mucosal Adjuvant" <i>J. Immunol.</i> 162:1959-1965.						
EXAMINER				DATE CONSIDERED			
<i>Dee llee</i>				<i>1/11/03</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0896K		SERIAL NO.: 09/768,917	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: VICARI et al.			
				FILING DATE: January 24, 2001		GROUP: TO BE ASSIGNED	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ	Lehner, T. et al., 2000, "Heat Shock Proteins Generate Beta-Chemokines which Function as innate adjuvants enhancing Adaptive Immunity" <i>Eur. J. Immunol.</i> 30:594-603.					
	AR	Lanig, J. et al., 1994, "Inhibition of in Vivo Tumor Growth by the Beta Chemokine, TCA3" <i>J. Immunol.</i> 153:4625-4635.					
	AS	Kim, J.J. et al., 2000, "Chemokine Gene Adjuvants can Modulate Immune Responses Induced by DNA Vaccines" <i>J. Interferon Cytokine Res.</i> 20:487-498.					
	AT	Braun, S.E. et al., 2000, "The CC Chemokine CK Beta-11/MIP-3 beta/ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells through NK Cells" <i>J. Immunol.</i> 164:4025-4031.					
	AU	Biragyn, A. et al., "Genetic Fusion of Chemokines to Self Tumor Antigen Induces Protective, T-Cell dependent Antitumor Immunity" <i>Nat. Biotechnol.</i> 17:253-258. (1999)					
	AV						
EXAMINER 				DATE CONSIDERED 1/11/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							